Synapse
⌘+K
Sign In
Sign Up for Free
Synapse
Sign In
Sign Up for Free
Home
Communities
Explore
More
Language
English
English
BioNTech (Germany)
h-index: 76
Total citations: 34,159
Total papers: 524
Homepage:
http://biontech.de/
Recent papers from BioNTech (Germany)
An Fc-inert mouse-human chimeric variant of DuoBody®-CD40x4-1BB exhibits in vivo antitumor activity and peripheral immune modulation
OncoImmunology · 2026
A Library of Potent TCRs Derived from Healthy Donors Targeting Kras G12d and G12v Neoantigens
Cancer Immunology Research · 2026
Beyond measurement: a strategic perspective on antibody–drug conjugates bioanalysis from the European Bioanalysis Forum
Bioanalysis · 2026
Cancer-specific T cell receptor discovery using 150,000 clinical genomics samples
Science Translational Medicine · 2026
RNA Vaccination Drives Expansion and Brain-Licensing of T Cells to Enhance the Efficacy of Adoptive Cell Therapy in Glioblastoma
Cancer Research · 2026
Building confidence in innovative vaccine technologies: how flexible, science-based USP standards help translate vaccine innovation into quality, consistency, and public trust
Vaccine Insights · 2026
BenchMHC: a reproducible framework for peptide-MHC presentation prediction
2026
Divergent Effects of Anti-CTLA4 and Anti-PD1 Blockade in the Tumor Microenvironment of Melanoma Metastases
Life · 2026
HexaBody-OX40 promotes antitumor immunity through FcγR crosslinking-independent OX40 agonist activity and enhances effects of PD-1 blocking antibodies
Clinical Cancer Research · 2026
Comparative analysis of ovarian cancer tumor-infiltrating T cells with those in melanoma and before and after PD-1 blockade
Cancer Research Communications · 2026
Messenger RNA delivery of a dual CD25/CD122 affinity-tuned IL-2 variant prolongs exposure and potentiates antitumor T cell immunity
Science Advances · 2026
Phase 3 Randomized Study Investigating the Safety, Tolerability, and Immunogenicity of a Combination Modified Messenger RNA Vaccine Against Influenza and COVID-19 in Healthy Adults
Vaccines · 2026
Transitioning from Impinging Jets to Single-Jet Impaction: Investigation of an Alternative Nozzle Design for the Respimat® Soft Mist Inhaler
European Journal of Pharmaceutical Sciences · 2026
Immunogenicity, Tolerability, and Safety of BA.1-Adapted BNT162b2 Vaccine in 18- to 55-Year-Olds Previously Vaccinated with BNT162b2 or Who Were COVID-19 Vaccine-Naive
Infectious Diseases and Therapy · 2026
Safety and Immunogenicity of the BNT162b2 COVID-19 Vaccine in Immunocompromised Participants 2 Years and Older: Results of an Open-Label Phase 2b Study
Vaccines · 2026
Chemically synthesized, non-capped and non-polyadenylated peptide-coding RNA efficiently induces antigen-specific CD8+ T cells
Nature Biomedical Engineering · 2026
Preclinical immunogenicity of the LP.8.1-adapted BNT162b2 COVID-19 vaccine
npj Vaccines · 2026
83RO Trastuzumab pamirtecan (T-Pam/DB-1303/BNT323) in patients (pts) with previously treated, HER2-expressing, advanced endometrial cancer (EC): Overall survival (OS) and efficacy in pt subgroups of a phase II dose-expansion cohort
ESMO Open · 2026
Mapping the immune landscape in small cell lung cancer unveils a distinct tumor-reactive CD8+ T cell molecular signature
2026
Tumor-naïve ctDNA detection with deep learning-enhanced error suppression for sensitive mutation calling
Genome Medicine · 2026